Corporate
2025.11.28
Lumosa has received the FDA’s feedback from the Type C consultation
The Company submitted a Type C meeting request to the U.S. Food and Drug Administration (FDA) for LT3001, its investigational therapy for acute ischemic stroke, based on the existing nonclinical data and clinical trial results.
Corporate
2025.11.28
Lumosa Has Received Feedback for the Type C Consultation from the US FDA
The Company submitted a Type C meeting request to the US FDA for LT3001, a novel therapy for acute ischemic stroke, based on the existing nonclinical data and clinical trial results.
Corporate
2025.11.04
Beach Cleanup!
Corporate
2025.10.28
Lumosa Share Positive P2 Trial Results
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001 (INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Finance
2025.10.20
Lumosa Announces Details of Upcoming 2025 Institutional Investor Conference
Corporate
2025.10.17
Announcement: Change in Company Spokesperson